 
                FULLHOPE BIOMEDICAL CO., LTD.
                                Update:2023/06/12
                            
                        Industries
                        
                    
                    Main Industry
                
                
                    Biotechnology
                
            
                    Main Product/Service
                
                
                    1. Diagnostic Tools
2. Immune Cell Therapy
3. Patents
            2. Immune Cell Therapy
3. Patents
                    Founded Year
                
                
                    2012
                
            
                    Unified Business No.
                
                
                    54151258
                
            
                    Status
                
                
Active                
            
                    Number of Employees
                
                
                    0
                
            
                    Total Paid-in
Capital
                
                
                    399,112,090 (NT$)
                
            
                        Location of Company
                    
                    
                        Taiwan
, New Taipei City                    
                
                    Exit Status
                
                
                    Emerging Stock Exchange(2025)
                
            
            Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
        
    
                Exclusive content for members
            
                
                    
                    Members-only content. Please log in to access.
                
        
                    Introduction
                
                
                        FHB focuses on the immune system related services and innovative R&D. Our goal is to establish the cell-based immunotherapies for cancers and autoimmune disorders.
                        
                        
                        
                        
                        
                    
                 
                         
                        